Clovis Oncology published the results lucitanib Phase 1 / 2a monotherapy study at ASCO

Clovis Oncology published the results lucitanib Phase 1 / 2a monotherapy study at ASCO -

Clovis Oncology (NASDAQ: CLVS) has today announced the results of an ongoing phase 1 / 2a study lucitanib assessment alone, the romance of the Company, a potent inhibitor of the tyrosine kinase activity of growth factor receptors fibroblasts 1-3 (FGFR1- 3) vascular receptors of endothelial growth factors 1 to 3 (VEGFR1-3) and platelet derived growth factor receptor alpha and beta (β PDGFRa). The study data were presented today during an oral presentation by Professor Jean-Charles Soria at the 2014 American Society of Clinical Oncology (ASCO) annual meeting.

"Treatment with lucitanib in this phase 1/2 clinical trial provided durable responses objective RECIST in patients with solid tumors. In particular, patients with advanced breast cancer with FGF receptor or FGF ligand changes experienced an objective response rate of 50% and progression-free survival of 9.6 months, "said Professor Carlos L. Arteaga, MD, associate director for clinical research Director of the Center for cancer targeted therapies and cancer Program Director within to Vanderbilt-Ingram Cancer Centre of Vanderbilt University . "Although the results to date of this ongoing clinical trial are early, they are always encouraging because they suggest that the determination of genetic alterations in the way of FGF might be important to identify the most likely to benefit from treatment with lucitanib cancer patients. "
" We are extremely encouraged by the response rate of 50 percent observed with lucitanib therapy in aberrant FGF patients heavily pre-treated, "said Patrick J. Mahaffy, President and Chief Officer of Clovis Oncology. "These results confirm the continued exploration of lucitanib in various tumor types with pathway activation of FGFR, and our Phase 2 program in breast cancer and non-small cancer squamous cell lung starts the registration shortly. in parallel, two trials on breast cancer are underway in Europe, sponsored by Servier our development partner ".
Lucitanib is a potent inhibitor of the receptor of the growth factor fibroblast 1-3 (FGFR1-3), vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and the derived growth factor receptors platelet alpha and beta (β PDGFRa). FGF, VEGF and PDGF cellular signaling pathways each play a role in tumor growth and angiogenesis. FGF related genetic changes, in particular, have been described in several types of cancer, including breast cancer and non small cell squamous lung, especially in the context of acquired resistance to initial therapy.
Over 100 patients were treated with lucitanib in this Phase 1 / 2a underway. All patients treated in the dose-expansion cohorts were identified as having aberrant FGF-sensitive solid tumor or angiogenesis. Patients in the 1 dose of the escalation phase study were treated with once daily (QD) dosage of 5 mg, 10 mg, 20 mg or 30 mg lucitanib, the data from which has led to a continuous recommended dose of 10 to 20mg QD cohort for the -expansion phase of the study.